Kilroy Realty Corporation with ticker code (KRC) have now 13 confirmed analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 52 and 32 suggesting an average Analsyt target price of $42.23. Now with the previous closing price of $30.54 and the analysts are correct then there would likely be a percentage uptick in value of 38.3%. The 50 day MA is $37.16 and the 200 moving average now moves to $44.15. The total market capitalization for the company now stands at $3,411m. Company Website: https://www.kilroyrealty.com
The potential market cap would be $4,717m based on the market consensus.
Kilroy Realty Corporation (NYSE: KRC, the company, KRC) is a leading West Coast landlord and developer, with a major presence in San Diego, Greater Los Angeles, the San Francisco Bay Area, and the Pacific Northwest. The company has earned global recognition for sustainability, building operations, innovation and design. As pioneers and innovators in the creation of a more sustainable real estate industry, the company’s approach to modern business environments helps drive creativity, productivity and employee retention for some of the world’s leading technology, entertainment, life science and business services companies. KRC is a publicly traded real estate investment trust (REIT) and member of the S&P MidCap 400 Index with more than seven decades of experience developing, acquiring and managing office and mixed-use projects. As of September 30, 2020, KRC’s stabilized portfolio totaled approximately 14.3 million square feet of primarily office and life science space that was 92.2% occupied and 95.5% leased. The company also had 808 residential units in Hollywood and San Diego, which had a quarterly average occupancy of 85.0% and 37.5%, respectively. In addition, KRC had seven in-process development projects with an estimated total investment of $1.9 billion, totaling approximately 2.3 million square feet of office and life science space. The office and life science space was 90% leased.
The company has a dividend yield of 7.37% with the ex dividend date set at 30-3-2023 (DMY).
Other points of data to note are a P/E ratio of 14.87, revenue per share of 9.39 and a 1.9% return on assets.
